Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

MET inhibitors in cancer: pitfalls and challenges.

Oliveres H, Pineda E, Maurel J.

Expert Opin Investig Drugs. 2019 Dec 6:1-13. doi: 10.1080/13543784.2020.1699532. [Epub ahead of print]

PMID:
31783719
2.

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.

Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2294. [Epub ahead of print]

PMID:
31465088
3.

The Tumor Microenvironment in Colorectal Cancer Therapy.

Pedrosa L, Esposito F, Thomson TM, Maurel J.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1172. doi: 10.3390/cancers11081172. Review.

4.

ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells.

de Barrios O, Sanchez-Moral L, Cortés M, Ninfali C, Profitós-Pelejà N, Martínez-Campanario MC, Siles L, Del Campo R, Fernández-Aceñero MJ, Darling DS, Castells A, Maurel J, Salas A, Dean DC, Postigo A.

Gut. 2019 Dec;68(12):2129-2141. doi: 10.1136/gutjnl-2018-317294. Epub 2019 Jul 31.

PMID:
31366457
5.

Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).

García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J.

Oncologist. 2019 Nov;24(11):e1115-e1122. doi: 10.1634/theoncologist.2018-0728. Epub 2019 Jun 24.

6.

Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma.

Diaz-Mercedes S, Archilla I, Camps J, de Lacy A, Gorostiaga I, Momblan D, Ibarzabal A, Maurel J, Chic N, Bombí JA, Balaguer F, Castells A, Aldecoa I, Borras JM, Cuatrecasas M.

Appl Health Econ Health Policy. 2019 Oct;17(5):655-667. doi: 10.1007/s40258-019-00482-7.

7.

The controversy of neoadjuvant therapy in rectal cancer.

Maurel J, Pedrosa L, Camps J.

Cir Esp. 2019 Aug - Sep;97(7):361-363. doi: 10.1016/j.ciresp.2019.01.004. Epub 2019 Feb 14. English, Spanish. No abstract available.

PMID:
30773234
8.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018).

Gómez-España MA, Gallego J, González-Flores E, Maurel J, Páez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R.

Clin Transl Oncol. 2019 Jan;21(1):46-54. doi: 10.1007/s12094-018-02002-w. Epub 2018 Dec 18.

9.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C.

Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.

10.

Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM).

Santaballa A, De Castro J, Maurel J, Lázaro M, Vera R, Alba E.

Clin Transl Oncol. 2019 Apr;21(4):534-538. doi: 10.1007/s12094-018-1951-z. Epub 2018 Oct 16.

PMID:
30327937
11.

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).

Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L.

Cancer Chemother Pharmacol. 2018 Dec;82(6):935-943. doi: 10.1007/s00280-018-3682-9. Epub 2018 Sep 17.

PMID:
30225601
12.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Ann Oncol. 2018 Oct 1;29(10):2121-2128. doi: 10.1093/annonc/mdy335.

PMID:
30165419
13.

Lithium as a disease-modifying agent for prion diseases.

Relaño-Ginés A, Lehmann S, Brillaud E, Belondrade M, Casanova D, Hamela C, Vincent C, Poupeau S, Sarniguet J, Alvarez T, Arnaud JD, Maurel JC, Crozet C.

Transl Psychiatry. 2018 Aug 22;8(1):163. doi: 10.1038/s41398-018-0209-4.

14.

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.

Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, Maurel J.

Neoplasia. 2018 Jul;20(7):678-686. doi: 10.1016/j.neo.2018.05.004. Epub 2018 May 26.

15.

Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.

García Del Muro X, Maurel J, Martínez Trufero J, Lavernia J, López Pousa A, de Las Peñas R, Cubedo R, Berros JP, Casado Herráez A, de Juan A, Martín Broto J.

Invest New Drugs. 2018 Jun;36(3):468-475. doi: 10.1007/s10637-018-0583-z. Epub 2018 Mar 12.

PMID:
29527631
16.

Surgical management of adolescent and young adults with gastrointestinal stromal tumors: it is of value?

Esposito F, Maurel J.

Transl Gastroenterol Hepatol. 2017 Nov 7;2:86. doi: 10.21037/tgh.2017.10.05. eCollection 2017. No abstract available.

17.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J.

Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9.

18.

Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.

Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA.

ESMO Open. 2017 Aug 3;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017.

19.

Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis.

Alberghina N, Sánchez-Montes C, Tuñón C, Maurel J, Araujo IK, Ferrer J, Sendino O, Córdova H, Vaquero EC, González-Suárez B, Martínez-Palli G, Ginès À, Fernández-Esparrach G.

Pancreatology. 2017 Sep - Oct;17(5):858-864. doi: 10.1016/j.pan.2017.08.004. Epub 2017 Aug 19.

PMID:
28844696
20.

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).

Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E, de Torres C.

Br J Cancer. 2017 Sep 5;117(6):767-774. doi: 10.1038/bjc.2017.252. Epub 2017 Aug 8.

21.

Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases.

Aranda E, Aparicio J, Bilbao JI, García-Alfonso P, Maurel J, Rodríguez J, Sangro B, Vieitez JM, Feliu J.

Future Oncol. 2017 Oct;13(23):2065-2082. doi: 10.2217/fon-2017-0220. Epub 2017 Jul 13. Review.

PMID:
28703622
22.

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.

Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J.

Tumour Biol. 2017 Jun;39(6):1010428317705509. doi: 10.1177/1010428317705509.

23.

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.

Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Martin N, Estevan R, Fernandez-Martos C.

Ann Oncol. 2017 Feb 1;28(2):344-353. doi: 10.1093/annonc/mdw616.

PMID:
28426108
24.

Clinical relevance of colorectal cancer molecular subtypes.

Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, García-Albéniz X, Maurel J, Batlle JF.

Crit Rev Oncol Hematol. 2017 Jan;109:9-19. doi: 10.1016/j.critrevonc.2016.11.007. Epub 2016 Nov 23. Review.

PMID:
28010901
25.

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).

Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL.

Clin Transl Oncol. 2016 Dec;18(12):1172-1178. doi: 10.1007/s12094-016-1586-x. Epub 2016 Nov 28.

26.

[Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma].

Martin-Richard M, Ginès A, Ayuso JR, Sabater L, Fabregat J, Mendez R, Fernández-Esparrach G, Molero X, Vaquero EC, Cuatrecasas M, Ferrández A, Maurel J; Comité multidisciplinar para la actualización de las recomendaciones para el manejo de las lesiones pre-malignas y el adenocarcinoma de páncreas.

Med Clin (Barc). 2016 Nov 18;147(10):465.e1-465.e8. doi: 10.1016/j.medcli.2016.07.033. Epub 2016 Oct 7. Spanish.

PMID:
27726847
27.

Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.

Caballero-Baños M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pagés M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, García-Albéniz X, Maurel J, Vilella R.

Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008. Epub 2016 Jul 16.

PMID:
27428073
28.

Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.

Maurel J, López-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E.

Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6. eCollection 2016.

29.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.

J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16.

PMID:
27185843
30.

Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system.

Mouri A, Legrand P, El Ghzaoui A, Dorandeu C, Maurel JC, Devoisselle JM.

Int J Pharm. 2016 Apr 11;502(1-2):117-24. doi: 10.1016/j.ijpharm.2016.01.072. Epub 2016 Feb 4.

PMID:
26836707
31.

Biliary tract cancers: SEOM clinical guidelines.

Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J.

Clin Transl Oncol. 2015 Dec;17(12):982-7. doi: 10.1007/s12094-015-1436-2. Epub 2015 Nov 25.

32.

Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.

Maurel J, Postigo A.

Curr Cancer Drug Targets. 2015;15(8):703-15. Review.

PMID:
26452385
33.

Development of pharmaceutical clear gel based on Peceol®, lecithin, ethanol and water: Physicochemical characterization and stability study.

Mouri A, Diat O, El Ghzaoui A, Ly I, Dorandeu C, Maurel JC, Devoisselle JM, Legrand P.

J Colloid Interface Sci. 2015 Nov 1;457:152-61. doi: 10.1016/j.jcis.2015.06.010. Epub 2015 Jun 17.

PMID:
26164247
34.

Endoluminal brachytherapy in the treatment of oesophageal cancer. Technique description, case report and review of the literature.

Castilla L, Rovirosa Á, Ginés À, Pages M, Camacho C, Quilis C, Pereira V, Maurel J, Biete A.

Rev Esp Enferm Dig. 2015 Jul;107(7):449-53. Review.

35.

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.

Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD.

Ann Oncol. 2015 Aug;26(8):1722-8. doi: 10.1093/annonc/mdv223. Epub 2015 May 8.

PMID:
25957330
36.

Chikungunya outbreak in Montpellier, France, September to October 2014.

Delisle E, Rousseau C, Broche B, Leparc-Goffart I, L'Ambert G, Cochet A, Prat C, Foulongne V, Ferre JB, Catelinois O, Flusin O, Tchernonog E, Moussion IE, Wiegandt A, Septfons A, Mendy A, Moyano MB, Laporte L, Maurel J, Jourdain F, Reynes J, Paty MC, Golliot F.

Euro Surveill. 2015 Apr 30;20(17). pii: 21108.

37.

ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.

Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, González-Vallinas M, Mendiola M, Burgos E, Aguayo C, Custodio AB, Machado I, Ramos D, Gironella M, Espinosa-Salinas I, Ramos R, Martín-Hernández R, Risueño A, De Las Rivas J, Reglero G, Yaya R, Fernández-Martos C, Aparicio J, Maurel J, Feliu J, Ramírez de Molina A.

Oncotarget. 2015 Mar 30;6(9):7348-63.

38.

LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.

Mezquita B, Pineda E, Mezquita J, Mezquita P, Pau M, Codony-Servat J, Martínez-Balibrea E, Mora C, Maurel J, Mezquita C.

Mol Carcinog. 2016 May;55(5):411-9. doi: 10.1002/mc.22289. Epub 2015 Feb 3.

PMID:
25647613
39.

Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).

Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J; Spanish Group for Research on Sarcoma (GEIS).

Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8. Epub 2015 Jan 22.

PMID:
25608769
40.

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.

Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J.

PLoS One. 2015 Jan 20;10(1):e0116527. doi: 10.1371/journal.pone.0116527. eCollection 2015.

41.

Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.

García-Albéniz X, Gallego R, Hofheinz RD, Fernández-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Ginés A, Miquel R, Pagés M, Pineda E, Pereira V, Sosa A, Reig O, Victoria I, Feliz L, María de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J.

World J Gastroenterol. 2014 Nov 14;20(42):15820-9. doi: 10.3748/wjg.v20.i42.15820.

42.

Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.

García-Albéniz X, Maurel J, Hernán MA.

Int J Cancer. 2015 May 15;136(10):2444-7. doi: 10.1002/ijc.29278. Epub 2014 Nov 3.

43.

Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.

Fernandez-Martos C, Brown G, Estevan R, Salud A, Montagut C, Maurel J, Safont MJ, Aparicio J, Feliu J, Vera R, Alonso V, Gallego J, Martin M, Pera M, Sierra E, Serra J, Delgado S, Roig JV, Santos J, Pericay C.

Oncologist. 2014 Oct;19(10):1042-3. doi: 10.1634/theoncologist.2014-0233. Epub 2014 Sep 10.

44.

Water solubilization capacity of pharmaceutical microemulsions based on Peceol®, lecithin and ethanol.

Mouri A, Diat O, Lerner DA, El Ghzaoui A, Ajovalasit A, Dorandeu C, Maurel JC, Devoisselle JM, Legrand P.

Int J Pharm. 2014 Nov 20;475(1-2):324-34. doi: 10.1016/j.ijpharm.2014.07.018. Epub 2014 Jul 15.

PMID:
25034800
45.

Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.

Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Rodríguez-Salas N, Burgos E, Ramos D, Calatrava A, Andrada E, Díaz-López E, Sánchez A, Madero R, Cejas P, Feliu J.

Mol Cancer Ther. 2014 Sep;13(9):2226-37. doi: 10.1158/1535-7163.MCT-13-1109. Epub 2014 Jun 30.

46.

First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.

Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Martínez-Marín V, Maurel J.

Br J Cancer. 2014 Jul 15;111(2):241-8. doi: 10.1038/bjc.2014.346. Epub 2014 Jun 19.

47.

RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.

Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J.

Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019. Epub 2014 May 12.

PMID:
24833563
48.

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

Garcia-Carbonero R, Rivera F, Maurel J, Ayoub JP, Moore MJ, Cervantes A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S, Tabernero J.

Oncologist. 2014 Apr;19(4):350-1. doi: 10.1634/theoncologist.2014-0028. Epub 2014 Mar 27.

49.

Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder.

Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C, Hamela C, Poupeau S, Laffont M, Gabelle A, Delaby C, Belondrade M, Arnaud JD, Alvarez MT, Maurel JC, Maurel P, Crozet C.

PLoS One. 2014 Feb 14;9(2):e88797. doi: 10.1371/journal.pone.0088797. eCollection 2014.

50.

A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.

Aparicio J, García-Mora C, Martín M, Petriz ML, Feliu J, Sánchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J.

PLoS One. 2014 Jan 9;9(1):e82209. doi: 10.1371/journal.pone.0082209. eCollection 2014.

Supplemental Content

Loading ...
Support Center